Commentary

iMedPub Journals
www.imedpub.com

Journal of Translational Neurosciences
ISSN 2573-5349

2022
Vol.7 No.6:003

Nano Medicine's Potentiality in Treating a Variety of Neurodegenerative and Cancerous Disorders

Md Habibur Rahman*

Department of Chemistry, University of Swabi, Pakhtunkhwa, Pakistan

***Corresponding author:** Md Habibur Rahman, Department of Chemistry, University of Swabi, Pakhtunkhwa, Pakistan Email: Rahmanhabib34@gmail.com

Received date: October 06, 2022, Manuscript No. IPNBT-22-15443; **Editor assigned date:** October 10, 2022, PreQC No. IPNBT-22-15443 (PQ); **Reviewed date:** October 17, 2022, QC No IPNBT-22-15443; **Revised date:** October 25, 2022, Manuscript No. IPNBT-22-15443(R); **Published date:** November 07, 2022, DOI: 10.36648/2573-5349.7.6.003

Citation: Rahman H Md (2022) Nano Medicine's Potentiality in Treating a Variety of Neurodegenerative and Cancerous Disorders. J Transl Neurosc Vol. 7 Iss No.6:003.

Description

One novel strategy for treating a wide range of diseases, including cancers, neurological issues, and infectious diseases, is nanoscale engineering. Because of their capacity to interface and activate potential targets while simultaneously limiting adverse effects, therapeutics for Neurodegenerative Diseases (NDs) can be altered in part. Since nanomaterials may play a significant role in medical transportation, they have been the subject of extensive research and application in cancer therapeutic strategies. Nanocarrier drug delivery has many advantages over conventional drug delivery, including high reliability, bioactivity, improved penetration and retention, precise targeting, and administration. Cancer treatment sensitivity in humans is caused by upregulation of drug efflux transporters, dysfunctional apoptotic mechanisms, and a hypoxic environment. Utilizing nanoparticles, it has been possible to enhance the efficacy of treatments for multidrug resistance by focusing on these pathways. Nanomaterials that target particular pathways of tumor resilience are being developed in response to the discovery of novel strategies for tumor chemoresistance. The use of nanoparticles in immunotherapy, which is becoming increasingly useful in the treatment of cancer, has only recently been the subject of research by scientists. This scientific literature has looked into nanoscale therapeutics, which is the most up-to-date treatments for cancer and neurodegenerative diseases. Various biomedical nanomaterials' potential for tissue regeneration, medication design, and the production of novel delivery strategies have also been emphasized, as have current findings.

History of Development of Treatments for Cancer and CNS Diseases

Neurological diseases account for 12% of all deaths worldwide and are a major cause of disability and death. Neuroinflammation (INF) has long been thought to be a common component of many neurological diseases, including MS, Alzheimer's, and Parkinson's disease. Because of the blood-mind hindrance, numerous possibly helpful meds for neurological illness can't enter the cerebrum in remedial amounts. Cancer is a disease with numerous complications because it affects millions of people of all ages and genders. One in four deaths are attributed to cancer, according to estimates. There are many different factors that can cause cancer, but genetics and the environment are the most important ones. Although there is a long history of development of treatments for cancer and CNS diseases, these treatments may be of little use to the majority of their users due to their low absorption rates, inadequate concentrations, and lack of tailored therapy. Thus, exceptional remedial procedures are extremely important to address the worries that most certainly kill wiped out tissues without influencing typical tissue. Chemists, pharmacists, and scientists from all over the world have spent the last few years working on the development of nanotechnology systems that could have an impact on a variety of medical fields, including medication delivery. As an alternative method for the targeted delivery of medications or macromolecules in the biological system, biopolymers as nanoparticles (NPs) are currently the subject of research. For both in vivo and in vitro applications, bioactive compounds can be produced with great success using biopolymer NPs.

Therapeutic Chemicals for Tumor Therapy

Nano biopolymers are also useful in the treatment of Enzyme Replacement (ERT). To date, numerous polymers have been utilized to control the release of biological or pharmaceutical substances. The three materials that are utilized the most frequently are polylactic acid, polyglycolic acid, and polylactic-co-glycolic acid. Despite being synthetic, these polymers are intriguing because they are biocompatible and biodegradable. This review will examine the various biomaterials utilized in nanomedicine, with a special focus on two drug delivery applications. In this way, a wide determination of nanomaterials is being researched for their capability to treat neurological problems and tumors. Although this was a long time ago, polymeric materials and drug administration systems have come a long way. We are able to supply these therapeutic chemicals for tumor therapy. These individualized delivery methods have been hampered by intrusions, inflammatory responses to implants, and a restricted diffusion area for therapeutic compounds. New treatment options for neurological diseases,

including cancer, have emerged as a result of nanotechnology-based medicine's prominence in medical science. However, there are still a few potential drawbacks, such as a lack of sophisticated equipment for precise and scalable nanomaterial synthesis, the difficulty of evaluating its safety and effectiveness, and some restrictions on particular materials. Tumor or neurological problems can be difficult to treat. As a result, multifunctional therapeutics were required, which nanomaterials could lessen.